Insilico has previously announced partnerships with Asia-based drugmakers including China Medical System 0867.HK and Japan's Takeda Pharmaceutical 4502.T.
"Together, we aim to build a scalable and repeatable model that can advance promising drug candidates more efficiently, positioning Bora at the forefront of AI-enabled pharmaceutical development and manufacturing, and establish a long-term growth platform through the development and commercialisation of high-value proprietary assets," Bora CEO Bobby Sheng said in a statement.
July 15 (Reuters) - Taiwan-based contract drugmaker Bora Pharmaceuticals 6472.TW will partner with Insilico Medicine 3696.HK on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully implemented, the drug discovery firm said on Wednesday.
